Alkermes plc. (ALKS) community

ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30213% above fair value

$46.98−0.91 (-1.90%)

Close on Nov 12, 2026Market cap $7.88BP/E 123.6Yield –

Community

Notes and questions about Alkermes from other investors

No posts about ALKS yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Alkermes's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on May 15, 2000
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALKS.

Compare: ALKS vs ACAD · ALKS vs SUPN · ALKS vs AXSM · ALKS vs INSM · ALKS vs AMRX

Revenue growth10.8% · median 16.3%

Gross margin84.6% · median 85.0%

Operating margin7.0% · median 10.2%

Net margin4.0% · median 4.2%

Company	Revenue	Growth
AMRX	$3.20B	+8.9%
ALKS	$1.67B	+10.8%
INSM	$1.52B	+240.0%
SUPN	$1.37B	+16.3%
ACAD	$1.20B	+14.8%
AXSM	$865.27M	+54.2%

Company

Next earnings (est.): Feb 24, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 2,050
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1520262

Advertisement
300 × 250

See a number that looks wrong?